Tazemetostat(TAZVERIK) is a novel EZH2 inhibitor that has shown significant efficacy and potential in the treatment of epithelioid sarcoma in recent years. As a targeted drug, Tazemetostat provides patients with new therapeutic options by inhibiting the activity of EZH2 enzyme.

Tazemetostat(TAZVERIK) shows significant efficacy and potential in the treatment of epithelioid sarcoma

Tazemetostat is an EZH2 inhibitor that blocks the growth and spread of lesion cells by inhibiting the activity of EZH2 enzymes. In recent years, Tazemetostat has shown significant efficacy and potential in the treatment of epithelioid sarcoma, especially in patients with metastatic or locally advanced epithelioid sarcoma that cannot be completely resected.

The mechanism of action of Tazemetostat

Tazemetostat selectively inhibits the activity of EZH2 enzymes and blocks the epigenetic regulation of lesion cells, thereby inhibiting the growth and spread of lesions. The EZH2 enzyme is overexpressed in many lesions, especially in epithelioid sarcoma, and the inhibitory effect of Tazemetostat can effectively slow the progression of the lesions.

Tazemetostat's indications

Tazemetostat is suitable for non-completely resectable metastatic or locally advanced epithelioid sarcoma in children and adults aged 16 years and older. It can also be used to treat recurrent or refractory follicular lymphoma (FL), especially in patients with positive EZH2 mutations.

Tazemetostat showed significant efficacy in the treatment of epithelioid sarcoma, but patients should pay attention to their possible side effects and related precautions when using it.

How to use Tazemetostat？

The recommended dose of Tazemetostat is 800mg twice daily, orally with oral administration with oral disposal until the disease progresses or unacceptable toxicity occurs. Patients should swallow the whole tablet when taking it, avoid cutting, crushing or chewing the tablets.

How to take Tazemetostat？

Tazemetostat should be taken twice a day at 800mg each time, oral can be taken with oral food. If you miss one dose or vomit after taking it, do not take it again, but you should continue to take the next dose according to the medication plan. Patients should monitor adverse reactions regularly during medication and adjust the dose according to the doctor's advice.

Dose adjustment

For patients with mild liver impairment, it is not recommended to adjust the Tazemetostat dose. Dosage adjustments in patients with moderate or severe liver impairment have not been determined and should be used under the guidance of a doctor. Patients with renal impairment do not need to adjust the dose.

The usage and dosage of Tazemetostat need to be adjusted according to the specific situation of the patient, especially for patients with liver function impairment. We will introduce the side effects and precautions of Tazemetostat.

Side effects and precautions of Tazemetostat

Patients should regularly monitor adverse reactions during use to prevent possible serious side effects.

Common side effects

Common side effects of Tazemetostat include pain, fatigue, nausea, decreased appetite, vomiting, and constipation. Patients should regularly monitor these adverse reactions during medication use, and adjust the dose or suspend the medication if necessary according to the doctor's advice.

Things to note

Tazemetostat may increase the risk of secondary malignant lesions. Patients should undergo regular examinations during use. Tazemetostatat has embryonic-fetal toxicity. Pregnant women and women with reproductive potential should take effective contraception during use. Lactation women should avoid breastfeeding during use.

Tazemetostat is a prescription drug. Patients should strictly follow the doctor's instructions when using it, conduct regular reviews to prevent possible serious adverse reactions.